Preclinical News and Research

RSS

Keryx Biopharmaceuticals initiates Phase 3 registration clinical trial for perifosine

Æterna Zentaris Inc., a global biopharmaceutical company focused on oncology and endocrine therapy, today announced the initiation, by its partner Keryx Biopharmaceuticals Inc., of a Phase 3 registration clinical trial for perifosine (KRX-0401), the Company's PI3K/Akt pathway inhibitor, in relapsed/refractory multiple myeloma patients.

16 Dec 2009

Naurex' GLYX-13 demonstrates antidepressant-like and anxiolytic-like activity without CNS-related side effects

Naurex Inc., a new clinical stage company developing innovative treatments for depression and other CNS disorders based on its novel GFPA NMDA receptor modulators, today announced that data presented at a major medical meeting showed that its lead compound GLYX-13 demonstrated robust antidepressant-like and anxiolytic-like activity with no signs of the CNS-related side effects seen with other drugs targeting the NMDA receptor.

16 Dec 2009

Roche's P2X3 receptor program for chronic pain licensed to Afferent Pharmaceuticals

Roche announced today it has licensed its P2X3 receptor program aimed at developing first-in-class treatments for chronic pain to Afferent Pharmaceuticals. Afferent was co-founded by Anthony Ford, Ph.D., Pappas Ventures, and Third Rock Ventures, and is focused on developing compounds that treat chronic pain by targeting a novel biological pathway.

16 Dec 2009

EDP Biotech develops a simple blood test for detecting early-stage colon cancer

Medical researchers with EDP Biotech Corporation (EDP) have captured national attention with their revolutionary new technology for a simple blood test to detect early-stage colon cancer.

16 Dec 2009

Cellular Dynamics International launches iCell Cardiomyocytes

Cellular Dynamics International (CDI) today announced the commercial launch of iCell(TM) Cardiomyocytes for use in testing of new drug candidates by the pharmaceutical industry.

16 Dec 2009

Preclinical study of Arno Therapeutics' drug candidate AR-42 presented at ASH 2009

Arno Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on oncology therapeutics, today announced the presentation of a poster at the annual American Society of Hematology (ASH) meeting that describes the preclinical activity of Arno’s drug candidate AR-42 against leukemia stem cells (LSCs).

16 Dec 2009

Repligen receives $731,000 to support ongoing development of new treatments for Friedreich's ataxia

Repligen Corporation today announced that the Company has received $731,000 in research funding to support the ongoing development of new treatments for Friedreich's ataxia from the Muscular Dystrophy Association (MDA).

16 Dec 2009

InSite Vision to advance new development candidate ISV-303

InSite Vision Incorporated, a company developing ophthalmic products for unmet eye care needs, today announced plans to advance new development candidate ISV-303, a topical anti-inflammatory product intended to reduce the pain and swelling associated with ocular surgery.

16 Dec 2009

AstraZeneca, UVa announce collaboration in development of new treatments for CAD and PAD

AstraZeneca and the University of Virginia (UVa) in Charlottesville, today announced that they have entered into a strategic research collaboration to enhance development of new treatments primarily for coronary artery disease (CAD) with a secondary focus on peripheral vascular disease (PAD).

15 Dec 2009

Femta Pharmaceuticals, Lonza Group collaborate in cGMP production of FM101 antibody

Femta Pharmaceuticals and Lonza Group Ltd jointly announce the execution of a manufacturing services agreement to facilitate the development and cGMP manufacturing of FM101. FM101 is a high affinity monoclonal antibody in late pre-clinical development for the treatment of Rheumatoid Arthritis.

15 Dec 2009

Genocea Biosciences to develop Chlamydia trachomatis vaccine with UPMC grant

Genocea Biosciences, a leading vaccine discovery and development company, today announced it has been awarded a grant from the University of Pittsburgh Medical Center’s (UPMC) Sexually Transmitted Infections (STI) Cooperative Research Center for the development of vaccines for Chlamydia trachomatis.

15 Dec 2009

Encouraging results from DAVANAT in combination with chemotherapies and biologics

Pro-Pharmaceuticals, Inc. today announced that the Brussels Branch of the Ludwig Institute of Cancer Research is testing the ability of DAVANAT® to stop Galectin-3 from blocking the immune system’s action on cancer cells. Peer reviewed studies have demonstrated that Galectin-1 and Galectin-3 induce apoptosis (cell death) in immune system T cells (“Galectins,” Chapter 7, Wiley, 2008).

15 Dec 2009

Cellular and subcellular effects of PACE technology presented

SANUWAVE Health, Inc., (www.sanuwave.com), an emerging medical technology company focused on the development and commercialization of non-invasive, biological response activating devices in the regenerative medicine area, announced that the cellular and subcellular effects of PACE™ technology were described during a lecture presented this past weekend.

15 Dec 2009

Lytix Biopharma AS receives approval to commence Phase I clinical trials of Oncopore

The Norwegian pharmaceutical company Lytix Biopharma AS today announced approvals from the Norwegian Medicines Agency (”Statens legemiddelverk”) and the Swedish Medical Products Agency (”Läkemedelverket”) to commence Phase I clinical trials of OncoporeTM (LTX-315) for the treatment of cancer.

15 Dec 2009

Cerebrospinal fluid signature and PiB imaging help predict Alzheimer's disease

Early Alzheimer's disease detected by a compound that binds to brain plaques appears likely to progress into symptomatic Alzheimer's disease with dementia, according to a report in the December issue of Archives of Neurology, one of the JAMA/Archives journals.

15 Dec 2009

Molecular Partners closes its CHF 46 million Series B equity investment round

Molecular Partners AG, a pioneer in the development of DARPins as next generation protein therapeutics, has announced the closing of its Series B equity investment round securing CHF 46 million (€ 30 million, $ 45 million).

15 Dec 2009

Merck granted exclusive license to Pfenex' Pseudomonas-based protein expression technology

Pfenex Inc. announced today that it has granted Merck & Co., Inc., through an affiliate, an exclusive worldwide license to Pfenex Expression Technology(TM) Pseudomonas-based recombinant protein expression technology for the production of specific proteins to be used in the development of an undisclosed vaccine candidate.

15 Dec 2009

New highly sensitive CFSE T cell proliferation assays launched by ProImmune

ProImmune Ltd, a leader in epitope discovery, immunogenicity and immune monitoring products and services, has launched CFSE T cell proliferation assays for immunogenicity risk assessment. The new highly sensitive assays form part of ProImmune’s REVEAL Immunogenicity System, a suite of tools used in the design and selection of biological drug leads at the preclinical stage.

15 Dec 2009

Bio-Quant becomes wholly-owned subsidiary of NexMed

NexMed, Inc., a developer of products based on the NexACT® technology, today announced the closing of its acquisition of Bio-Quant, Inc., a privately-held leading research organization for in vitro and in vivo contract drug discovery and pre-clinical development services, headquartered in San Diego, CA. Upon closing, Bio-Quant became a wholly-owned subsidiary of NexMed.

15 Dec 2009

ALS TDI and Applied Proteomics join to identify protein biomarkers associated with ALS

The ALS Therapy Development Institute (ALS TDI) and Applied Proteomics, Inc. announced today that they have completed the first stage of a multi-year collaboration to identify and validate protein biomarkers associated with amyotrophic lateral sclerosis (ALS, Lou Gehrig's disease).

15 Dec 2009

Preclinical News and Research

Keryx Biopharmaceuticals initiates Phase 3 registration clinical trial for perifosine

Naurex' GLYX-13 demonstrates antidepressant-like and anxiolytic-like activity without CNS-related side effects

Roche's P2X3 receptor program for chronic pain licensed to Afferent Pharmaceuticals

EDP Biotech develops a simple blood test for detecting early-stage colon cancer

Cellular Dynamics International launches iCell Cardiomyocytes

Preclinical study of Arno Therapeutics' drug candidate AR-42 presented at ASH 2009

Repligen receives $731,000 to support ongoing development of new treatments for Friedreich's ataxia

InSite Vision to advance new development candidate ISV-303

AstraZeneca, UVa announce collaboration in development of new treatments for CAD and PAD

Femta Pharmaceuticals, Lonza Group collaborate in cGMP production of FM101 antibody

Genocea Biosciences to develop Chlamydia trachomatis vaccine with UPMC grant

Encouraging results from DAVANAT in combination with chemotherapies and biologics

Cellular and subcellular effects of PACE technology presented

Lytix Biopharma AS receives approval to commence Phase I clinical trials of Oncopore

Cerebrospinal fluid signature and PiB imaging help predict Alzheimer's disease

Molecular Partners closes its CHF 46 million Series B equity investment round

Merck granted exclusive license to Pfenex' Pseudomonas-based protein expression technology

New highly sensitive CFSE T cell proliferation assays launched by ProImmune

Bio-Quant becomes wholly-owned subsidiary of NexMed

ALS TDI and Applied Proteomics join to identify protein biomarkers associated with ALS

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest Life Science News